McKesson Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Is It Time To Reassess McKesson (MCK) After Recent Share Price Pullback?

AI-generated analysis

πŸ“‰ McKesson (MCK) recently saw its share price drop 1.2% over seven days and 6.0% over the past month from a last close of $873.43.

πŸ“ˆ Despite the short-term pullback, the stock has returned 6.1% year-to-date, 29.1% over one year, 143.1% over three years, and significantly more over five years.

πŸ’‘ Sector interest remains high due to attention on scale, supply chain efficiency, and long-term positioning in healthcare distribution.

πŸ“Š A Discounted Cash Flow (DCF) model based on Free Cash Flow to Equity projects an intrinsic share value of $1,521.24.

πŸ’° This implies McKesson is trading at a 42.6% discount relative to the DCF model's estimated fair value.

πŸ“ˆ The P/E ratio stands at 24.65x, which is higher than the Healthcare industry average of 22.60x but lower than the peer group average of 26.91x.

πŸ“Š Simply Wall St calculates a proprietary Fair Ratio of 33.24x based on earnings growth and risk factors, suggesting current shares trade below that level.

🧠 Investors can evaluate valuation through "Narratives" linking analyst price targets (ranging from $860 to $1,107) with financial forecasts.

πŸ” Valuation approaches include adjusting for company-specific characteristics like biosimilar optionality and potential regulatory concerns.

⚠️ The article is general commentary based on historical data and does not constitute financial advice or a recommendation to buy or sell.

πŸ“‰ McKesson delivered annual Free Cash Flow of approximately $9.61 billion in the latest twelve months, with projected growth to $7.17 billion by 2030.

πŸ₯ Continued investor focus is on which distributors are attractively priced given sector-wide cost pressures and policy discussions.

πŸ“ˆ Management's efficiency gains and supply chain capabilities continue to drive positive long-term positioning for the company.

Bullish Signals
  • ,.
  • ,.
  • ,.
  • s P/E ratio of 24.65x sits below Simply Wall St.
  • ,.
  • ,.
Risk Factors
  • McKesson's share price has declined over the last 30 days by 6.0%, indicating recent market weakness despite long-term gains.
  • The stock trades at a P/E ratio of 24.65x, which is above the broader Healthcare industry average of 22.60x and only slightly below its peer group average of 26.91x.
  • Some analyst price targets for McKesson sit as low as US$860.00, reflecting concerns around regulation and consolidation that could impact valuation.
  • The article notes that valuation analysis may not factor in the latest price-sensitive company announcements or qualitative material, creating a potential blind spot in investment assessment.
Full Analysis
McKesson Corporation (MCK) has experienced a recent share price pullback, with the stock closing at US$873.43 after declining 1.2% over seven days and 6.0% over 30 days. Despite these short-term drops, the company remains in a positive long-term trajectory, having delivered returns of 6.1% year to date, 29.1% over the past year, 143.1% over three years, and significantly higher gains over five years. This recent market movement occurs against a backdrop of sustained investor interest in large healthcare distributors, with focus remaining on how scale, operational efficiency, and supply chain capabilities influence long-term positioning amidst sector-wide cost pressures and ongoing policy discussions. According to analysis by Simply Wall St, McKesson holds a value score of 4 out of 6 and appears potentially undervalued based on a Discounted Cash Flow model using a 2 Stage Free Cash Flow to Equity approach. Based on projected free cash flow estimates ranging from US$4.65 billion in 2026 to around US$7.17 billion by 2030, the model calculates an intrinsic value of approximately US$1,521.24 per share. This figure suggests the current trading price represents a discount of roughly 42.6% relative to the estimated fair value derived from future cash flow projections. Valuation metrics also indicate the stock trades at a Price-to-Earnings ratio of 24.65x, which is higher than the broader Healthcare industry average of 22.60x but lower than the peer group average of 26.91x. Simply Wall St's proprietary Fair Ratio assessment places McKesson at 33.24x, suggesting the current P/E multiple remains below what their model implies should be supported by the company's growth profile and risk characteristics. The article concludes by emphasizing that investors may consider alternative narratives, such as varying analyst price targets ranging from US$860.00 to US$1,107.00, which reflect differing views on regulatory risks, consolidation dynamics, and potential efficiencies or biosimilar options, noting that these narratives help contextualize the gap between current market price and fair value estimates.